Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease.
Katharina DörrAlexander KainzRainer OberbauerPublished in: Current opinion in nephrology and hypertension (2022)
Data from a recent trial of etelcalcetide on LVH suggest that FGF23 may be a possible therapeutic target for cardiac risk reduction in patients on haemodialysis. If these findings are confirmed by further research, it might be speculated that a treatment shift from active vitamin D towards FGF23-lowering therapy may occur in patients on haemodialysis.
Keyphrases
- prognostic factors
- left ventricular
- end stage renal disease
- peritoneal dialysis
- heart failure
- chronic kidney disease
- clinical trial
- stem cells
- acute myocardial infarction
- machine learning
- newly diagnosed
- big data
- ejection fraction
- mesenchymal stem cells
- study protocol
- aortic stenosis
- phase ii
- patient reported outcomes
- aortic valve
- combination therapy
- replacement therapy
- catheter ablation